Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

NCT06911684 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer Patients

Interventions

COMBINATION_PRODUCT: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy
COMBINATION_PRODUCT: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy

Sponsor

Sun Yat-sen University